Molecular analysis of <i>Kras</i> and <i>Nras</i> mutations in a series of 720 patients for guiding the treatment of metastatic colorectal cancer in Turkey.

Karadayi, H.; Aktas, Cigdem; Alkac, Mert; Ozon, Y.H.; Berkil, Hakan

doi:10.1200/jco.2016.34.15_suppl.e13115

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found the incidence of KRAS mutations to be 45% and this result was similar to other studies in Turkey. [ 27 , 28 ] A single KRAS mutation was determined in 90% of patients, of which 92% had a mutation in exon 2, 4% in exon 3 and 4% in exon 4. 10% of patients had multiple KRAS mutations.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer

et al. 2020

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer in the world and is the second leading cause of cancer-related deaths. Several mutations are involved in the development of CRC. The prognostic significance of the KRAS mutation has been discussed in many studies. We aimed to investigate the prognostic significance of the number of KRAS mutations in metastatic CRC (mCRC). Patients with mutations in the KRAS gene were included in the study. They were divided into 2 groups as single mutation and multiple mutations in the KRAS gene. For the study, 425 CRC patients were screened. KRAS mutation was positive in 191 patients (45%). One hundred ninety-one patients were included in the study, 171 patients (90%) had single mutations and 20 patients (10%) had multiple mutations. Median progression-free survival was 12.8 months in patients with multiple mutations, while it was 8.8 months in patients with single mutations ( P : .05). The median overall survival of patients with multiple mutations was 40.7 months, while it was 22.7 months for patients with single mutations ( P = .01) We found that the presence of multiple mutations in KRAS mutant patients was associated with better overall survival and progression-free survival than a single mutation.

show abstract

Section: Discussionmentioning

confidence: 99%